Trial Profile
A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of Rifampicin (a CYP3A4 Inducer) on the Pharmacokinetics of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary) ; Rifampicin
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 18 Jun 2021 Status changed from active, no longer recruiting to completed.
- 11 Mar 2021 Planned End Date changed from 5 Mar 2021 to 31 Dec 2021.
- 07 Jan 2020 Planned End Date changed from 31 Dec 2019 to 5 Mar 2021.